Targeted induction of apoptosis for cancer therapy: current progress and prospects

Trends in Molecular Medicine

Volumn 12, Issue 8, 2006, Pages 382-393

  Bremer, Edwin ^a   van Dam, Go ^a   Kroesen, Bart Jan ^a   de Leij, Lou ^a   Helfrich, Wijnand ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMICYN; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; ANTIBODY; ANTINEOPLASTIC AGENT; ANTISENSE HYPOXIA INDUCIBLE FACTOR 1ALPHA; APOLIZUMAB; BORTEZOMIB; CD22 EXOTOXIN A; FAS LIGAND; GALECTIN 1; GALECTIN 3; GEFITINIB; GEMTUZUMAB OZOGAMICIN; HGS ETR 1; HGS ETR 2; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; OBLIMERSEN; P53 DEPENDENT REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1; PROTEASOME INHIBITOR; PX 478; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL FATE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DEREGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; GALECTINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 33746741050     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.06.002     Document Type: Review

References (80)

1. Breckenridge D., and Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr. Opin. Cell Biol. 16 (2004) 647-652
2. Schimmer A. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64 (2004) 7183-7190
3. O'Brate A., and Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code?. Drug Resist. Updat. 6 (2003) 313-322
4. Schimmer A.D., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
5. Yang L., et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 63 (2003) 6815-6824
6. Sievers E. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol. Dis. 31 (2003) 7-10
7. DiJoseph J., et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103 (2004) 1807-1814
8. Kreitman R.J., et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23 (2005) 6719-6729
9. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
10. Byrd J., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
11. Mone A., et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 103 (2004) 1846-1854
12. Friedlos F., et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 62 (2002) 1724-1729
13. Asklund T., et al. Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp. Cell Res. 284 (2003) 185-195
14. Eggermont A., et al. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 4 (2003) 429-437
15. Timmer T., et al. Fas receptor-mediated apoptosis: a clinical application?. J. Pathol. 196 (2002) 125-134
16. Greaney P., et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk. Res. 30 (2006) 415-426
17. Kelley S.K., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31-38
18. Muhlenbeck F., et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J. Biol. Chem. 275 (2000) 32208-32213
19. Kelley R., et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280 (2005) 2205-2212
20. MacFarlane M., et al. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65 (2005) 11265-11270
21. Wajant H., et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20 (2001) 4101-4106
22. Bremer E., et al. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int. J. Cancer 109 (2004) 281-290
23. Bremer E., et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 280 (2005) 10025-10033
24. Samel D., et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 278 (2003) 32077-32082
25. Bremer E., et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res. 65 (2005) 3380-3388
26. Bremer E., et al. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6 (2004) 636-645
27. Bremer E., et al. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107 (2005) 2863-2870
28. Le L.H., et al. Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignacies or non-Hodgkin's lyphoma (NHL). J. Clin. Oncol. 22 (2004) 2533 (ASCO Meeting Abstracts)
29. de Bono J., et al. 6 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNFα-related apoptosis inducing ligand receptor 2 (TRAIL-R2) in patients with advanced cancer. Eur. J. Cancer Suppl. 2 (2004) 61 (Meeting Abstracts)
30. Takeda K., et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199 (2004) 437-448
31. Lane D., et al. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol. Cancer Ther. 5 (2006) 509-521
32. Horak P., et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol. Cancer Res. 3 (2005) 335-343
33. Liu F., and Rabinovich G. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5 (2005) 29-41
34. Mallucci L., et al. Turning cell cycle controller genes into cancer drugs: A role for an antiproliferative cytokine (βGBP). Biochem. Pharmacol. 66 (2003) 1563-1569
35. Hahn H.P., et al. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ. 11 (2004) 1277-1286
36. Ravatn R., et al. Circumventing multidrug resistance in cancer by β-galactoside binding protein, an antiproliferative cytokine. Cancer Res. 65 (2005) 1631-1634
37. Rubinstein N., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004) 241-251
38. Rabinovich G., et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16 (2006) 210-220
39. Mani A., and Gelmann E. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23 (2005) 4776-4789
40. Kane R., et al. Velcade(R): U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8 (2003) 508-513
41. Fernandez Y., et al. Differential regulation of noxa in normal melanocytes and melanoma Cells by proteasome inhibition: therapeutic implications. Cancer Res. 65 (2005) 6294-6304
42. Ling Y., et al. Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 9 (2003) 1145-1154
43. Brooks A.D., et al. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann. N. Y. Acad. Sci. 1059 (2005) 160-167
44. Badros A., et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. 23 (2005) 4089-4099
45. Walensky L., et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305 (2004) 1466-1470
46. Oltersdorf T., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
47. Fleischer B., et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 28 (2006) 25-32
48. Del Bufalo D., et al. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22 (2003) 8441-8447
49. Bockbrader K., et al. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24 (2005) 7381-7388
50. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5 (2005) 761-772
51. Ramanathan R., et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 11 (2005) 3385-3391
52. Grbovic O.M., et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 57-62
53. Castro J., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106 (2005) 2506-2512
54. Chen G., et al. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell 9 (2002) 401-410
55. Wang X., et al. 17-Allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-Induced lung cancer cell death by blocking the nuclear factor-κB pathway. Cancer Res. 66 (2006) 1089-1095
56. Vogelstein B., et al. Surfing the p53 network. Nature 408 (2000) 307-310
57. Vassilev L., et al. in vivo Activation of the p53 Pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
58. Issaeva N., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
59. Bykov V., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002) 282-288
60. Schnitzer S.E., et al. Hypoxia and HIF-1α protect A549 cells from drug-induced apoptosis. Cell Death. Differ. (2006) 10.1038/sj.cdd.4401864
61. Leek R.D., et al. The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway. Cancer Res. 65 (2005) 4147-4152
62. Welsh S., et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol. Cancer Ther. 3 (2004) 233-244
63. Sun X., et al. Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8 (2001) 638-645
64. Baylin S., and Ohm J. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006) 107-116
65. Graff J.R., et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55 (1995) 5195-5199
66. Issa J., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23 (2005) 3948-3956
67. Tamm I., et al. Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann. Hematol. 84 Suppl. 13 (2005) 47-53
68. Minucci S., and Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
69. Kuendgen A., et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol. 84 Suppl. 13 (2005) 61-66
70. Dokmanovic M., and Marks P.A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96 (2005) 293-304
71. Insinga A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11 (2005) 71-76
72. Nebbioso A., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11 (2005) 77-84
73. Nakata S., et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23 (2004) 6261-6271
74. Yu X., et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94 (2002) 504-513
75. Yang H., et al. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk. Res. 29 (2005) 739-748
76. Blagosklonny M.V. Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacol. Sci. 26 (2005) 77-81
77. Blagosklonny M.V. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 3 (2004) 1035-1042
78. Blagosklonny M.V. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 23 (2004) 2967-2975
79. Gerspach, J. et al. 2005. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. 13, 273-284.
80. Azam M., et al. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843